CN105492011A - 不理想给药化学化合物的治疗增效 - Google Patents

不理想给药化学化合物的治疗增效 Download PDF

Info

Publication number
CN105492011A
CN105492011A CN201480032586.8A CN201480032586A CN105492011A CN 105492011 A CN105492011 A CN 105492011A CN 201480032586 A CN201480032586 A CN 201480032586A CN 105492011 A CN105492011 A CN 105492011A
Authority
CN
China
Prior art keywords
alkylating agent
group
gives
mustard
pharmacotherapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480032586.8A
Other languages
English (en)
Chinese (zh)
Inventor
丹尼斯·M·布朗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN105492011A publication Critical patent/CN105492011A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480032586.8A 2013-04-08 2014-04-08 不理想给药化学化合物的治疗增效 Pending CN105492011A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361809627P 2013-04-08 2013-04-08
US61/809,627 2013-04-08
PCT/US2014/033391 WO2014168986A1 (en) 2013-04-08 2014-04-08 Therapeutic benefit of suboptimally administered chemical compounds

Publications (1)

Publication Number Publication Date
CN105492011A true CN105492011A (zh) 2016-04-13

Family

ID=51689967

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480032586.8A Pending CN105492011A (zh) 2013-04-08 2014-04-08 不理想给药化学化合物的治疗增效

Country Status (7)

Country Link
US (3) US11491154B2 (enExample)
EP (1) EP2983674A4 (enExample)
JP (2) JP2016519684A (enExample)
KR (1) KR20160061911A (enExample)
CN (1) CN105492011A (enExample)
AU (4) AU2014251038A1 (enExample)
WO (1) WO2014168986A1 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109562118A (zh) * 2016-06-29 2019-04-02 株式会社生物制药治疗 非口服给药用医药组合物
CN109628570A (zh) * 2018-12-07 2019-04-16 南方医科大学南方医院 一种检测TRIM29基因Tyr544Cys突变的试剂盒及其用途
CN112638424A (zh) * 2018-08-27 2021-04-09 斯玛特迪利弗利有限责任公司 以聚次甲基染料靶向治疗败血性胆汁淤积的pkc抑制剂
CN113929081A (zh) * 2021-10-13 2022-01-14 西南大学 上下转换双发射全色光谱碳点及其合成方法和应用
CN114425054A (zh) * 2022-01-20 2022-05-03 中国人民解放军军事科学院军事医学研究院 一种蛋白酶体抑制剂Bortezomib在抗辐射损伤中的用途
CN117205225A (zh) * 2023-09-12 2023-12-12 湖南普瑞玛药物研究中心有限公司 栀子苷在制备治疗骨髓增殖性肿瘤药物中的应用
CN117860948A (zh) * 2024-03-12 2024-04-12 江西永通科技股份有限公司 一种医用复合功能型抗菌敷料及其制备方法

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2686520T3 (enExample) 2011-06-06 2018-03-17
WO2014179528A2 (en) * 2013-05-01 2014-11-06 Brown Dennis M Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions
HUE066123T2 (hu) 2013-06-13 2024-07-28 Akebia Therapeutics Inc Készítmények és módszerek anémia kezelésére
CN105764491A (zh) 2013-12-09 2016-07-13 度瑞公司 药物活性剂复合物、聚合物复合物，以及包括其的组合物和方法
CA2974691A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
MX374909B (es) * 2015-04-01 2025-03-06 Akebia Therapeutics Inc El uso del inhibidor de propil hidrolasa del factor inducible de hipoxia (hif) para el tratamiento o prevención de la anemia.
EP3118621A1 (en) * 2015-07-14 2017-01-18 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Methods and compositions for the diagnosis and for the treatment of adrenoleukodystrophy
US10449269B2 (en) * 2016-08-29 2019-10-22 Yale University Particle conjugated prosthetic patches and methods of making and using thereof
MX2019011496A (es) 2017-03-27 2020-01-23 Tesaro Inc Composiciones de niraparib.
KR20200052349A (ko) 2017-09-11 2020-05-14 아토사 테라퓨틱스, 인크. 엔독시펜을 제조 및 사용하는 방법
BR112020006039A2 (pt) * 2017-09-26 2020-10-06 Tesaro, Inc. formulações de niraparibe
EP3773502A4 (en) * 2018-04-06 2022-05-18 UCAR Health GmbH TREATMENT OF CANCER BY GUANIDINIUM DERIVATIVES
IL278533B1 (en) 2018-05-09 2025-10-01 Akebia Therapeutics Inc Process for the preparation of 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
CN108754160B (zh) * 2018-07-26 2020-05-08 江苏理工学院 一种吡哆醛含锰废水的回收利用方法
CN109394692B (zh) * 2018-12-12 2020-09-25 中国药科大学 达沙替尼接枝型聚合物胶束、其冻干粉针剂及制备方法和应用
JP7157263B2 (ja) 2019-07-01 2022-10-19 オークウッド ラボラトリーズ，エル．エル．シー． ミクロスフェア及びエマルションを製造するためのシステム及び方法
US12201591B2 (en) 2019-07-03 2025-01-21 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen
CN110491443B (zh) * 2019-07-23 2022-04-01 华中师范大学 一种基于投影邻域非负矩阵分解的lncRNA蛋白质关联预测方法
MA57563A1 (fr) * 2020-01-30 2022-10-31 Purcann Pharma Inc Procédé de prévention ou de réduction de la décomposition de la biomasse de cannabaceae
CN113045550A (zh) * 2021-03-12 2021-06-29 深圳济康医药科技有限公司 一种三氮唑类衍生物及其制备方法和应用
CN117794544A (zh) * 2021-09-08 2024-03-29 卫材R&D管理有限公司 实体瘤治疗用医药组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012024367A2 (en) * 2010-08-18 2012-02-23 Del Mar Pharmaceuticals Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol
US20120207857A1 (en) * 2006-08-18 2012-08-16 University Of North Texas Health Science Center At Fort Worth Compositions and Methods for Potentiation of Cancer Agents

Family Cites Families (234)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2969364A (en) 1957-12-26 1961-01-24 Upjohn Co Derivatives of 5-amino uracil
US3008491A (en) 1959-05-04 1961-11-14 Chapman Valve Mfg Co Valve for concentric pipe lines
US3012976A (en) 1959-11-02 1961-12-12 Miles Lab Specific test composition for occult blood
US3008281A (en) 1960-07-14 1961-11-14 Nat Dairy Prod Corp Conveyor
US3299104A (en) 1963-04-09 1967-01-17 Leo Ab Certain steroid nu-bis-(haloethyl)-carbamates
JPS59186924A (ja) 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5035878A (en) 1988-09-12 1991-07-30 University Of Rochester Use of dithiocarbamates to counteract myelosuppression
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5395855A (en) 1990-05-07 1995-03-07 Ciba-Geigy Corporation Hydrazones
US5484612A (en) 1993-09-22 1996-01-16 The Board Of Trustees Of The Leland Stanford Junior University Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
DK0836605T3 (da) 1995-07-06 2002-05-13 Novartis Ag Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
US6011069A (en) 1995-12-26 2000-01-04 Nisshin Flour Milling Co., Ltd. Multidrug resistance inhibitors
US20020077461A1 (en) 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
ES2263178T3 (es) 1996-06-27 2006-12-01 Chugai Seiyaku Kabushiki Kaisha Remedios para mieloma para ser utilizados junto con agentes antitumorales de mostaza nitrogenada.
US6121245A (en) 1997-01-29 2000-09-19 Firshein; Richard N. Method of treating cancer using alkylglycerols in conjunction with chemotherapy
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US20040072889A1 (en) 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
EP1019034A2 (en) 1997-07-01 2000-07-19 Atherogenics, Inc. Antioxidant enhancement of therapy for hyperproliferative conditions
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
CA2329130A1 (en) 1998-05-21 1999-11-25 Isis Pharmaceuticals Inc. Compositions and methods for non-parenteral delivery of oligonucleotides
AU4543899A (en) 1998-06-08 1999-12-30 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
KR20000011247A (ko) * 1998-07-23 2000-02-25 김윤 다당류를이용한대장선택성약물전달조성물및약학제제
EP1107964B8 (en) 1998-08-11 2010-04-07 Novartis AG Isoquinoline derivatives with angiogenesis inhibiting activity
US6326390B1 (en) 1998-08-25 2001-12-04 King Pharmaceuticals Reseach And Development, Inc. Use of adenosine A3 receptor antagonists to inhibit tumor growth
EP1165085B1 (en) 1999-03-30 2006-06-14 Novartis AG Phthalazine derivatives for treating inflammatory diseases
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
US8791081B2 (en) 1999-08-13 2014-07-29 Case Western Reserve University MGMT inhibitor combination for the treatment of neoplastic disorders
US7811981B2 (en) 1999-08-30 2010-10-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods of and compositions for inhibiting the proliferation of mammalian cells
US20030072794A1 (en) 2000-06-09 2003-04-17 Teni Boulikas Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
ATE465756T1 (de) 2000-06-23 2010-05-15 Mitsubishi Tanabe Pharma Corp Antitumoreffekt-verstärker
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
CN101317825A (zh) 2000-10-30 2008-12-10 欧罗赛铁克股份有限公司 控释氢可酮制剂
ITMI20002358A1 (it) 2000-10-31 2002-05-01 Flavio Moroni Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi
US7619005B2 (en) 2000-11-01 2009-11-17 Cognition Pharmaceuticals Llc Methods for treating cognitive impairment in humans with Multiple Sclerosis
US20100098691A1 (en) 2001-01-24 2010-04-22 S'bio Pte Ltd Combination of benzimidazole anti-cancer agent and a second anti-cancer agent
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
IL159048A0 (en) 2001-06-21 2004-05-12 Genentech Inc Sustained release formulation
US20030158118A1 (en) 2001-11-26 2003-08-21 Weidner Morten Sloth Combination of cimetidine and cysteine derivatives for treating cancer
US7045534B2 (en) 2002-02-12 2006-05-16 The Board Of Trustees Of The Leland Stanford Junior University Methods of reducing angiogenesis
EP2138575B8 (en) 2002-02-20 2013-07-24 Mersana Therapeutics, Inc. Conjugates comprising a biodegradable polymer and uses therefor
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
DE60332762D1 (de) 2002-11-12 2010-07-08 Jewish General Hospital Montre Kombination von stickstoff-senf analogen und imatinib für die behandlung von chronischer lymphatischer leukämie
ATE449081T1 (de) 2002-12-30 2009-12-15 Celgene Corp Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen
DK1603570T5 (da) 2003-02-26 2013-12-09 Sugen Inc Aminoheteroarylforbindelser som proteinkinaseinhibitorer
US20070207952A1 (en) 2003-03-24 2007-09-06 Sequoia Pharmaceuticals Long Acting Biologically Active Conjugates
CA2520586C (en) 2003-03-27 2011-06-14 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
WO2004103958A2 (en) 2003-05-19 2004-12-02 Michigan State University Preparation of hymenialdisine derivatives and use thereof
US7842835B2 (en) 2003-07-07 2010-11-30 Georgetown University Histone deacetylase inhibitors and methods of use thereof
ES2317047T3 (es) 2003-08-07 2009-04-16 Schering Corporation Nuevos inhibidores de la farnesil proteina transferasa como agentes antitumorales.
AU2004270187A1 (en) 2003-09-04 2005-03-17 Aventis Pharmaceuticals Inc. Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP)
HUP0303313A2 (hu) 2003-10-09 2005-07-28 Richter Gedeon Vegyészeti Gyár Rt. Transzdermális gyógyszerkészítmények
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
US8652484B2 (en) 2004-02-13 2014-02-18 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US8435539B2 (en) 2004-02-13 2013-05-07 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
WO2005092326A1 (en) 2004-03-22 2005-10-06 The Regents Of The University Of Michigan Small molecule antagonists of xiap family proteins
JP4993374B2 (ja) 2004-04-05 2012-08-08 メルク エイチディーエーシー リサーチ エルエルシー ヒストン脱アセチル化酵素インヒビタープロドラッグ
TW200538149A (en) 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
TW200600091A (en) 2004-05-21 2006-01-01 Telik Inc Sulfonylethyl phosphorodiamidates
CA2569826C (en) 2004-06-30 2013-07-16 Janssen Pharmaceutica N.V. Substituted 2-alkyl quinazolinone derivatives as parp inhibitors
AU2005269716B2 (en) 2004-07-20 2011-01-27 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
SE0402025D0 (sv) 2004-08-13 2004-08-13 Active Biotech Ab Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
WO2006031806A2 (en) 2004-09-10 2006-03-23 Atherogenics, Inc. 2-thiopyrimidinones as therapeutic agents
WO2006078711A2 (en) 2005-01-19 2006-07-27 Mgi Gp, Inc. Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting parp
CN101142198B (zh) 2005-02-17 2012-10-31 辛塔制药公司 用于治疗疾病的异*唑坎布雷它斯丁衍生物
US7872050B2 (en) 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
US7638558B2 (en) 2005-04-01 2009-12-29 Intezyne Technologies, Inc. Polymeric micelles for drug delivery
US20060229277A1 (en) 2005-04-08 2006-10-12 Orbus Pharma, Inc. Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
WO2006110683A1 (en) 2005-04-11 2006-10-19 Abbott Laboratories 2-substituted-1h-benzimidazole-4-carboxamides are parp inhibitors
US8242103B2 (en) 2005-05-19 2012-08-14 Merck Sharp & Dohme Limited Sulphamides for treatment of cancer
ES2392544T3 (es) 2005-06-07 2012-12-11 Yale University Métodos de tratamiento del cáncer y otras enfermedades o estados patológicos usando LFMAU y LDT
BRPI0612138B8 (pt) 2005-06-15 2021-05-25 Cardiome Pharma Corp compostos éter aminocicloexílicos e método para fazer os mesmos
HRP20110804T1 (hr) 2005-06-23 2011-11-30 Merck Sharp & Dohme Corp. Benzocikloheptapiridini kao inhibitori receptora tirozin kinaze met
PT3248613T (pt) 2005-07-18 2022-03-16 Seagen Inc Conjugados de ligante de fármaco e beta-glucuronida
US7700773B2 (en) 2005-09-09 2010-04-20 Schering Corporation 4-cyano, 4-amino, and 4-aminomethyl derivatives of pyrazolo[1,5-a]pyridines, pyrazolo[1,5-c]pyrimidines and 2H-indazole compounds and 5-cyano, 5-amino, and 5-aminomethyl derivatives of imidazo[1,2-a]pyridines, and imidazo[1,5-a]pyrazines as cyclin dependent kinase inhibitors
US8378117B2 (en) 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
CA2626016A1 (en) 2005-10-21 2007-06-21 Panacea Biotec Limited Pharmaceutical composition comprising at least one anticancer drug and at least one polymer
CN101316597B (zh) 2005-11-03 2013-04-17 顶点医药品公司 用作激酶抑制剂的氨基嘧啶
EP1948132B1 (en) 2005-11-18 2009-08-05 Synhton B.V. Zolpidem tablets
CA2633500A1 (en) 2005-12-20 2007-07-05 President And Fellows Of Harvard College Compounds, screens, and methods of treatment
WO2007081751A2 (en) 2006-01-05 2007-07-19 The Johns Hopkins University Compositions and methods for the treatment of cancer
US7910607B2 (en) * 2006-03-10 2011-03-22 The Trustees Of California State University Nitroxide free radical synergized antineoplastic agents
EP2001400B1 (en) 2006-03-14 2014-05-07 Neuren Pharmaceuticals Limited Oral formulations of glycyl-2-methylprolyl-glutamate
WO2007107545A1 (en) 2006-03-22 2007-09-27 Janssen Pharmaceutica N.V. Cyclic-alkylaminederivatives as inhibitors of the interaction between mdm2 and p53
JP2009531364A (ja) 2006-03-28 2009-09-03 ノバルティス アクチエンゲゼルシャフト アミド誘導体およびｇタンパク質関連疾患の処置のためのそれらの使用
CN101415409B (zh) 2006-04-05 2012-12-05 诺瓦提斯公司 用于治疗癌症的治疗剂的组合
CA2649861A1 (en) 2006-04-26 2007-11-08 Merck & Co., Inc. Disubstituted aniline compounds
GB0609378D0 (en) 2006-05-11 2006-06-21 Novartis Ag Organic compounds
US8119652B2 (en) 2006-05-18 2012-02-21 Merck Sharp & Dohme Corp. Aryl-fused spirocyclic compounds
US8034834B2 (en) 2006-05-25 2011-10-11 Synta Pharmaceuticals Corp. Method for treating proliferative disorders with HSP90 inhibitors
EP2038262B1 (en) 2006-05-25 2014-11-12 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
JP5284955B2 (ja) 2006-06-20 2013-09-11 アボット・ラボラトリーズ Ｐａｒｐ阻害剤としてのピラゾロキナゾリノン
US7964728B2 (en) 2006-07-06 2011-06-21 Solvay Pharmaceuticals B.V. Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition
US20080213249A1 (en) 2006-07-07 2008-09-04 The Scripps Research Insitute Use of Retro-Aldol Reaction to Generate Reactive Vinyl Ketone for Attachment to Antibody Molecules by Michael Addition Reaction for Use in Immunostaining and Immunotargeting
TW200813021A (en) 2006-07-10 2008-03-16 Merck & Co Inc Tyrosine kinase inhibitors
WO2008009407A2 (en) 2006-07-17 2008-01-24 Novartis Ag Sulphonylaminocarbonyl derivatives of bile acid amides for use as immunomodulators
EP2049563B1 (en) 2006-07-24 2014-03-12 Tetralogic Pharmaceuticals Corporation Dimeric iap antagonists
JP2010500370A (ja) 2006-08-07 2010-01-07 ピーディーエル バイオファーマ，インコーポレイティド 多発性硬化症を処置するための抗ｃｓ１抗体を用いる組成物および方法
US7683060B2 (en) 2006-08-07 2010-03-23 Incyte Corporation Triazolotriazines as kinase inhibitors
CA2659425C (en) 2006-08-17 2017-06-20 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
ES2375284T3 (es) 2006-08-23 2012-02-28 Eisai R&D Management Co., Ltd. Sal de un derivado de fenoxipiridina, o cristal de la misma, y procedimiento de producción de la misma.
RU2009110243A (ru) 2006-08-23 2010-09-27 Новартис АГ (CH) Амиды как ингибиторы сфингомиелина
US7956064B2 (en) 2006-09-01 2011-06-07 Cylene Pharmaceuticals, Inc. Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators
WO2008030408A2 (en) 2006-09-05 2008-03-13 Yale University Proteomimetic compounds as inhibitors of the interaction of a nuclear receptor with coactivator peptides
EP2526934B1 (en) 2006-09-22 2015-12-09 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
JP5721949B2 (ja) 2006-10-12 2015-05-20 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 複合薬剤
US8242080B2 (en) 2006-10-13 2012-08-14 The Regents Of The University Of California Inhibitors of the EGFR kinase targeting the asymmetric activating dimer interface
TWI404716B (zh) 2006-10-17 2013-08-11 Kudos Pharm Ltd 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
US7842278B2 (en) 2006-10-27 2010-11-30 Natural Pharmacia International, Inc. Hypoxia-selective, weakly basic 2-nitroimidazole delivery agents and methods of use thereof
CN101573345A (zh) 2006-10-31 2009-11-04 先灵公司 作为蛋白激酶抑制剂的2-氨基噻唑-4-甲酰胺
CA2667487C (en) 2006-11-06 2017-04-04 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
US20120164075A1 (en) 2006-11-21 2012-06-28 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of mammalian diseases
US20080125397A1 (en) 2006-11-28 2008-05-29 Telik, Inc. 2 (SULFONYL)ETHYL N,N,N',N' tetrakis(2 chloroethyl)phosphorodia
US7655799B2 (en) 2006-11-29 2010-02-02 Telik, Inc. 2{[2-(substituted amino)ethyl]sulfonyl}ethyl N,N,N',N'-tetrakis(2-chloroethyl)phosphorodiamidates
WO2008079973A2 (en) 2006-12-21 2008-07-03 Centocor, Inc. Egfr binding peptides and uses thereof
US8834920B2 (en) 2006-12-21 2014-09-16 Alza Corporation Liposome composition for targeting egfr receptor
US20080293648A1 (en) 2007-01-05 2008-11-27 Saha Pharmaceuticals, Inc. Compositions and Methods for Cancer Treatment
US8470323B2 (en) 2007-01-09 2013-06-25 The Trustees Of The University Of Pennsylvania Drug delivery to human tissues by single chain variable region antibody fragments cloned by phage display
US8398956B2 (en) 2007-01-11 2013-03-19 Immunomedics, Inc. In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
CA2676145A1 (en) 2007-02-06 2008-08-14 Novartis Ag 1-benzenesulfonyl-1h-indole derivatives as inhibitors of ccr9 activity
EP2491923A3 (en) 2007-02-15 2012-12-26 Novartis AG Combinations of therapeutic agents for treating cancer
CA2677046A1 (en) 2007-02-28 2008-09-04 Inotek Pharmaceuticals Corporation Indenoisoquinolinone analogs and methods of use thereof
ES2381446T3 (es) 2007-03-08 2012-05-28 Janssen Pharmaceutica, N.V. Derivado de quinolinona como inhibidores de PARP y TANK
CA2783589A1 (en) 2007-03-09 2008-09-18 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
WO2008112277A2 (en) 2007-03-13 2008-09-18 Wake Forest University Compositions and methods for treating cancer
US20100184706A1 (en) 2007-03-20 2010-07-22 Bachovchin William W Fap-activated chemotherapeutic compounds, and methods of use thereof
ES2430614T3 (es) 2007-04-10 2013-11-21 Exelixis, Inc. Métodos de tratamiento del cáncer usando inhibidores de piridopirimidinona de PI3K alfa
BRPI0810195A2 (pt) 2007-04-13 2014-12-30 Novartis Ag Moduladores de gpbar1
CN101663033B (zh) 2007-04-18 2013-01-16 默沙东公司 作为smo拮抗剂的三唑衍生物
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
AT505225A1 (de) 2007-04-26 2008-11-15 Sanochemia Pharmazeutika Ag 0erfahren zur herstellung von hoch reinem 2,4'-dimethyl-3-piperidino-propiophenon (tolperison), dieses enthaltende pharmazeutische zusammensetzungen, sowie tolperison enthaltende wirkstoffformulierungen
US7838495B2 (en) 2007-04-27 2010-11-23 University Of Maryland, Baltimore Compositions and methods of use of EPB1, and ErbB3 binding protein
JP5389785B2 (ja) 2007-05-02 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用なチアゾールおよびピラゾール
AU2008254273B2 (en) 2007-05-15 2013-03-28 Otsuka Pharmaceutical Co., Ltd. Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
WO2008144506A1 (en) 2007-05-16 2008-11-27 University Of Maryland, Baltimore Apoptotic pathway targeting for the diagnosis and treatment of cancer
US20110288023A1 (en) 2007-06-08 2011-11-24 The Regents Of The University Of California Office Of Technology Transfer Cancer drug delivery using modified transferrin
WO2009003911A1 (en) 2007-06-29 2009-01-08 4Sc Ag Thiophene-imidazopyridines
JP2010532756A (ja) 2007-07-06 2010-10-14 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ｍＴＯＲＣ１及びｍＴＯＲＣ２の両方の阻害剤を含む組み合わせ抗癌療法
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
KR20100053607A (ko) 2007-08-03 2010-05-20 패시트 바이오테크 코포레이션 항-ｔｗｅａｋ 수용체 항체의 치료 용도
ES2514517T3 (es) 2007-08-10 2014-10-28 Mitsubishi Tanabe Pharma Corporation Nueva sal de compuesto de isoquinolina y cristal de la misma
HUE027443T2 (en) 2007-09-10 2016-10-28 Boston Biomedical Inc A novel class of Stat3 pathway inhibitors and tumor stem cell inhibitors
SI2209375T1 (sl) 2007-10-03 2014-12-31 Eisai Inc. Spojine inhibitorja PARP in metode uporabe
WO2009045504A1 (en) 2007-10-04 2009-04-09 President And Fellows Of Harvard College Methods and compositions for treating cancer and modulating signal transduction and metabolism pathways
CN101903403B (zh) 2007-10-19 2016-03-16 西雅图基因公司 Cd19结合剂及其应用
WO2009054941A1 (en) 2007-10-25 2009-04-30 Merck & Co., Inc. Therapeutic compounds
CA2705509A1 (en) 2007-11-14 2009-05-22 Forerunner Pharma Research Co., Ltd. Diagnosis and treatment of cancer using anti-gpr49 antibody
US8268827B2 (en) 2007-11-15 2012-09-18 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa. Pyridazinone derivatives as PARP inhibitors
US8088749B2 (en) 2007-12-12 2012-01-03 The Regents Of The University Of Michigan Compositions and methods for treating cancer
WO2009082662A1 (en) 2007-12-21 2009-07-02 Novartis Ag Combination of nilotinib and a nitrogen mustard analogue for the treatment of chronic lymphocytic leukemia
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
JP2011511078A (ja) 2008-02-06 2011-04-07 レアド トヘラペウトイクス，インコーポレーテッド ポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）のベンズオキサゾールカルボキサミド阻害剤
WO2009099677A2 (en) 2008-02-08 2009-08-13 Aileron Therapeutics, Inc. Therapeutic peptidomimetic macrocycles
WO2009102707A2 (en) 2008-02-11 2009-08-20 Auspex Pharmaceuticals, Inc. Substituted oxazaphosphorines
EP2259791A2 (en) 2008-03-05 2010-12-15 Tel HaShomer Medical Research Infrastructure and Services Ltd. Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer
MX2010010012A (es) 2008-03-11 2010-10-20 Incyte Corp Derivados de azetidina y ciclobutano como inhibidores de jak.
RU2506267C2 (ru) 2008-03-31 2014-02-10 Дженентек, Инк. Бензопирановые и бензоксепиновые ингибиторы рi3k и их применение
EP2110377A1 (en) 2008-04-15 2009-10-21 DAC S.r.l. Spirocyclic derivatives as histone deacetylase inhibitors
CN102076717B (zh) 2008-04-30 2016-02-03 伊缪诺金公司 交联剂和它们的用途
WO2009143018A2 (en) 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
US8207169B2 (en) 2008-06-03 2012-06-26 Msd K.K. Substituted [1,2,4]triazolo[4′,3′:1,6]pyrido[2,3-b]pyrazines of the formula D
GB2460672B (en) 2008-06-04 2012-01-04 Gw Pharma Ltd Cannabinoids in combination with non-cannabinoid chemotherapeutic agents that are alkylating agents
EP2133334A1 (en) 2008-06-09 2009-12-16 DAC S.r.l. Heterocyclic derivatives as HDAC inhibitors
US8207195B2 (en) 2008-06-26 2012-06-26 Inspire Pharmaceuticals, Inc. Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds
SG192485A1 (en) 2008-07-08 2013-08-30 Incyte Corp 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
CA2730377C (en) 2008-07-11 2017-09-19 Neumedics Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits
EP2307413B1 (en) 2008-07-15 2015-09-09 F. Hoffmann-La Roche AG Novel phenyl-imidazopyridines and pyridazines
MX2011000661A (es) 2008-07-16 2011-05-25 Pharmacyclics Inc Inhibidores de tirosina cinasa de bruton para el tratamiento de tumores solidos.
US8217076B2 (en) 2008-07-17 2012-07-10 Colorado State University Research Foundation Method for preparing largazole analogs and uses thereof
US20120230991A1 (en) 2008-07-29 2012-09-13 Douglas Kim Graham Methods and compounds for enhancing anti-cancer therapy
WO2010021822A2 (en) 2008-07-30 2010-02-25 The Regents Of The University Of California Discovery of candidate biomarkers of in vivo apoptosis by global profiling of caspase cleavage sites
WO2010014913A1 (en) 2008-08-01 2010-02-04 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
EP2326650B9 (en) 2008-08-06 2014-09-10 BioMarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
NZ591113A (en) 2008-08-26 2012-07-27 Boehringer Ingelheim Int Thienopyrimidine linked to phenyl or pyridine via an nh amine for pharmaceutical compositions
US20100068302A1 (en) 2008-09-17 2010-03-18 Traslational Cancer Drugs Pharma, S.L. Methods and compositions for the treatment of cancer
CN102177140B (zh) 2008-10-08 2016-01-27 赛福伦公司 用于制备苯达莫司汀的方法
US20100111901A1 (en) 2008-11-03 2010-05-06 Auspex Pharmaceuticals, Inc. Triazole inhibitors of aromatase
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
UY32240A (es) 2008-11-14 2010-06-30 Boeringer Ingelheim Kg Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
WO2010068920A2 (en) 2008-12-12 2010-06-17 Auspex Pharmaceutical, Inc. Diaminoquinazoline inhibitors of dihydrofolate reductase
WO2010080570A2 (en) 2008-12-18 2010-07-15 New York University Tumor therapy with antitumor agents in combination with sindbis virus-based vectors
US20100173013A1 (en) 2009-01-08 2010-07-08 Denis Drygin Treatment of neoplastic disorders using combination therapies
BRPI1007358A2 (pt) 2009-01-23 2018-03-06 Takeda Pharmaceutical Company Limited inibidores de poli (adp-ribose) polimerase (parp)
HRP20151325T1 (hr) 2009-01-23 2016-01-01 Rigel Pharmaceuticals, Inc. Pripravci i postupci za inhibiciju jak puta
CN104523661A (zh) 2009-02-06 2015-04-22 南加利福尼亚大学 含有单萜的治疗组合物
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
RU2011141123A (ru) 2009-03-11 2013-04-20 Плексксикон, Инк. ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-b]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RAF-КИНАЗ
EP2413901A4 (en) 2009-03-30 2015-05-06 Cerulean Pharma Inc POLYMER CONCRETE CONJUGATES, PARTICLES, COMPOSITIONS AND CORRESPONDING USES
WO2010114805A1 (en) 2009-03-31 2010-10-07 The Trustees Of The University Of Pennsylvania Methods of treating cancer with phenformin
US8680139B2 (en) 2009-04-01 2014-03-25 Progenra Anti-neoplastic compounds, compositions and methods
EP2417123A2 (en) 2009-04-06 2012-02-15 Agios Pharmaceuticals, Inc. Therapeutic compositions and related methods of use
US8377962B2 (en) 2009-04-08 2013-02-19 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US20100291025A1 (en) 2009-04-13 2010-11-18 Auspex Pharmaceuticals, Inc. Indazole inhibitors of tyrosine kinase
SG175287A1 (en) 2009-04-24 2011-11-28 Hoffmann La Roche Inhibitors of bruton's tyrosine kinase
US20110053968A1 (en) 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
US9151762B2 (en) 2009-06-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Identification of DSG-3 as a biomarker for the detection of metastasis in lymph nodes
TWI625121B (zh) 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
US8232318B2 (en) 2009-07-31 2012-07-31 The General Hospital Corporation Approaches to treat cancer using HB-EGF inhibitors
MY161541A (en) * 2009-07-31 2017-04-28 Shin Maeda Cancer metastasis inhibitor
EP2470546B1 (en) 2009-08-28 2013-07-24 Takeda Pharmaceutical Company Limited Hexahydrooxazinopteridine compounds for use as mtor inhibitors
CN102625803A (zh) 2009-09-11 2012-08-01 赛林药物股份有限公司 药学上有用的杂环-取代的内酰胺
BR112012005970A2 (pt) 2009-09-16 2015-09-08 Cylene Pharmaceuticals Inc moduladores tricíclicos de proteína quinase
ES2444779T3 (es) 2009-09-28 2014-02-26 F. Hoffmann-La Roche Ag Compuestos de benzoxazepina inhibidores de la PI3K y su utilización en el tratamiento de cáncer
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
WO2011050242A1 (en) 2009-10-23 2011-04-28 Millennium Pharmaceuticals, Inc. Anti-gcc antibody molecules and related compositions and methods
EP2501412B1 (en) 2009-11-18 2017-03-29 Nektar Therapeutics Salt form of a multi-arm polymer-drug conjugate
JP5802676B2 (ja) 2009-12-04 2015-10-28 センワ バイオサイエンシズ インコーポレイテッド Ｃｋ２阻害剤としてのピラゾロピリミジンおよび関連複素環化合物
US20110195066A1 (en) 2010-02-05 2011-08-11 Auspex Pharmaceuticals, Inc. Quinoline inhibitors of tyrosine kinase
CA3162668A1 (en) 2010-02-12 2011-08-18 Gentelon, Inc. Compositions and methods for treating depression
US20110206661A1 (en) 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Trimethoxyphenyl inhibitors of tyrosine kinase
AR080328A1 (es) 2010-02-26 2012-03-28 Boehringer Ingelheim Int Tienopirimidinas que contienen un grupo alquilo sustituido inhibidoras de quinasas mnk1 y/o mnk2, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de trastornos metabolicos tales como diabetes y obesidad, y trastornos hiperproliferativos, entre otros
UY33241A (es) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
CN103002742B (zh) 2010-03-05 2016-07-13 卡尔约药物治疗公司 核转运调节剂及其应用
AU2011243947A1 (en) 2010-04-23 2012-12-06 Piramal Enterprises Limited Nitric oxide releasing prodrugs of therapeutic agents
WO2011143422A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated 2 -aminopyridine derivatives useful as inhibitors of atr kinase
WO2011150073A2 (en) 2010-05-26 2011-12-01 Shriners Hospitals For Children Compositions comprising the nc2 domain of collagen ix and methods of using same
NZ604040A (en) 2010-06-03 2015-02-27 Pharmacyclics Inc The use of inhibitors of bruton’s tyrosine kinase (btk)
WO2012047339A2 (en) 2010-06-28 2012-04-12 The General Hospital Corporation Anti-cxcr4 as a sensitizer to cancer therapeutics
WO2012044832A1 (en) 2010-09-30 2012-04-05 Fetzer Oliver S Methods of treating a subject and related particles, polymers and compositions
US8846623B2 (en) 2010-10-25 2014-09-30 Academia Sinica Cancer-targeting peptides and uses thereof in cancer treatment and diagnosis
CN103298474B (zh) 2010-11-10 2016-06-29 无限药品股份有限公司 杂环化合物及其用途
SI2786753T1 (sl) 2010-11-12 2019-05-31 Pharma Mar S.A. Kombinacijska terapija s protitumorskim antibiotikom
US20140088021A1 (en) 2011-05-27 2014-03-27 Nektar Therapeutics Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds
US8637490B2 (en) 2011-07-01 2014-01-28 Uwm Research Foundation, Inc. Anti-cancer agents
EP2734228A4 (en) 2011-07-18 2015-04-08 Ohio State Innovation Foundation FTY720 INCREASES CD74 RECEPTOR EXPRESSION AND SENSITIZES CANCER CELLS TO CELL DEATH INDUCED BY ANTI-CD74 ANTIBODIES
CN110711188A (zh) * 2012-01-20 2020-01-21 德玛公司 经取代的己糖醇类用于治疗恶性肿瘤的用途
KR101374820B1 (ko) 2012-01-30 2014-03-17 광주과학기술원 페오포르바이드-α 컨쥬게이트 및 그의 용도
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
EA201492082A1 (ru) 2012-06-04 2015-03-31 Фармасайкликс, Инк. Кристаллические формы ингибитора тирозинкиназы брутона
US20140005148A1 (en) 2012-06-29 2014-01-02 Coldstream Laboratories Inc. Stable liquid formulations of nitrogen mustards

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120207857A1 (en) * 2006-08-18 2012-08-16 University Of North Texas Health Science Center At Fort Worth Compositions and Methods for Potentiation of Cancer Agents
WO2012024367A2 (en) * 2010-08-18 2012-02-23 Del Mar Pharmaceuticals Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109562118A (zh) * 2016-06-29 2019-04-02 株式会社生物制药治疗 非口服给药用医药组合物
US11986530B2 (en) 2016-06-29 2024-05-21 Therabiopharma Inc. Drug composition for parenteral administration
CN112638424A (zh) * 2018-08-27 2021-04-09 斯玛特迪利弗利有限责任公司 以聚次甲基染料靶向治疗败血性胆汁淤积的pkc抑制剂
CN109628570A (zh) * 2018-12-07 2019-04-16 南方医科大学南方医院 一种检测TRIM29基因Tyr544Cys突变的试剂盒及其用途
CN113929081A (zh) * 2021-10-13 2022-01-14 西南大学 上下转换双发射全色光谱碳点及其合成方法和应用
CN114425054A (zh) * 2022-01-20 2022-05-03 中国人民解放军军事科学院军事医学研究院 一种蛋白酶体抑制剂Bortezomib在抗辐射损伤中的用途
CN117205225A (zh) * 2023-09-12 2023-12-12 湖南普瑞玛药物研究中心有限公司 栀子苷在制备治疗骨髓增殖性肿瘤药物中的应用
CN117205225B (zh) * 2023-09-12 2024-05-31 湖南普瑞玛药物研究中心有限公司 栀子苷在制备治疗骨髓增殖性肿瘤药物中的应用
CN117860948A (zh) * 2024-03-12 2024-04-12 江西永通科技股份有限公司 一种医用复合功能型抗菌敷料及其制备方法
CN117860948B (zh) * 2024-03-12 2024-06-04 江西永通科技股份有限公司 一种医用复合功能型抗菌敷料及其制备方法

Also Published As

Publication number Publication date
US11491154B2 (en) 2022-11-08
EP2983674A4 (en) 2017-05-10
AU2014251038A1 (en) 2015-11-26
AU2024200650A1 (en) 2024-02-22
AU2021257978A1 (en) 2021-11-25
US20230133044A1 (en) 2023-05-04
US12336993B2 (en) 2025-06-24
JP2016519684A (ja) 2016-07-07
AU2019240599A1 (en) 2019-10-17
JP2019135268A (ja) 2019-08-15
US20160045502A1 (en) 2016-02-18
WO2014168986A1 (en) 2014-10-16
KR20160061911A (ko) 2016-06-01
EP2983674A1 (en) 2016-02-17
US20250312347A1 (en) 2025-10-09

Similar Documents

Publication Publication Date Title
US12336993B2 (en) Therapeutic benefit of suboptimally administered chemical compounds
US20200206188A1 (en) Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
AU2019283893B2 (en) Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor
JP6280546B2 (ja) ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
CN112472699A (zh) 改善比生群及衍生物的治疗益处的组合方法
CN106659765A (zh) 二脱水半乳糖醇及其类似物或衍生物用于治疗非小细胞肺癌和卵巢癌的用途
TW201722421A (zh) 雙脫水半乳糖醇或其衍生物和類似物藉由ｄｎａ損傷之誘導和細胞周期之延宕治療非小細胞肺癌、神經膠母細胞瘤及卵巢癌之用途
AU2024200718A1 (en) Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol
HK1224581A1 (en) Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brian tumor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160413